Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report

Disease progression during immunotherapy in colorectal cancer does not always indicate treatment failure. A case argues that carcinoembryonic antigen (CEA) may serve as an early marker to distinguish between pseudoprogression and real progression. Presentation of results from reintroduction of chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Trabjerg, Natacha Dencker, Rask, Christina, Jensen, Lars Henrik, Hansen, Torben Frøstrup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637362/
https://www.ncbi.nlm.nih.gov/pubmed/31360509
http://dx.doi.org/10.1002/ccr3.2262
_version_ 1783436228853497856
author Trabjerg, Natacha Dencker
Rask, Christina
Jensen, Lars Henrik
Hansen, Torben Frøstrup
author_facet Trabjerg, Natacha Dencker
Rask, Christina
Jensen, Lars Henrik
Hansen, Torben Frøstrup
author_sort Trabjerg, Natacha Dencker
collection PubMed
description Disease progression during immunotherapy in colorectal cancer does not always indicate treatment failure. A case argues that carcinoembryonic antigen (CEA) may serve as an early marker to distinguish between pseudoprogression and real progression. Presentation of results from reintroduction of chemotherapy after progression on immunotherapy that suggest increased efficiency.
format Online
Article
Text
id pubmed-6637362
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-66373622019-07-29 Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report Trabjerg, Natacha Dencker Rask, Christina Jensen, Lars Henrik Hansen, Torben Frøstrup Clin Case Rep Case Reports Disease progression during immunotherapy in colorectal cancer does not always indicate treatment failure. A case argues that carcinoembryonic antigen (CEA) may serve as an early marker to distinguish between pseudoprogression and real progression. Presentation of results from reintroduction of chemotherapy after progression on immunotherapy that suggest increased efficiency. John Wiley and Sons Inc. 2019-06-18 /pmc/articles/PMC6637362/ /pubmed/31360509 http://dx.doi.org/10.1002/ccr3.2262 Text en © 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Trabjerg, Natacha Dencker
Rask, Christina
Jensen, Lars Henrik
Hansen, Torben Frøstrup
Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
title Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
title_full Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
title_fullStr Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
title_full_unstemmed Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
title_short Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
title_sort pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637362/
https://www.ncbi.nlm.nih.gov/pubmed/31360509
http://dx.doi.org/10.1002/ccr3.2262
work_keys_str_mv AT trabjergnatachadencker pseudoprogressionduringtreatmentwithpembrolizumabfollowedbyrechallengewithchemotherapyinmetastaticcolorectalcanceracasereport
AT raskchristina pseudoprogressionduringtreatmentwithpembrolizumabfollowedbyrechallengewithchemotherapyinmetastaticcolorectalcanceracasereport
AT jensenlarshenrik pseudoprogressionduringtreatmentwithpembrolizumabfollowedbyrechallengewithchemotherapyinmetastaticcolorectalcanceracasereport
AT hansentorbenfrøstrup pseudoprogressionduringtreatmentwithpembrolizumabfollowedbyrechallengewithchemotherapyinmetastaticcolorectalcanceracasereport

Ejemplares similares